Skip to main content

MIC Capital Management UK LLP

13F filer · CIK 0001889830
Reported Aug 10, 2026
Net seller this quarter
13F portfolio value$394MU.S. long equity reported on 13F
Positions163 new · 1 closed
Net flow last quarter-$77.4MBuys minus sells
Top 10 positions weight94.6%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 10, 202616 positions
HAYWHayward Holdings, Inc.$107M27.09%2.88%-6.1%Q3 2024
RVMDRevolution Medicines, Inc.$99.6M25.25%0.25%-33.2%Q4 2023
RXRXRecursion Pharmaceuticals, Inc.$35.4M8.98%1.81%0.0%Q4 2021
QSRRestaurant Brands International Inc.$28M7.10%0.11%Not reportedQ4 2021
CPNGCoupang, Inc.$24.5M6.22%Not reportedNot reportedQ4 2021
GRABGrab Holdings Ltd$18.9M4.78%Not reportedNot reportedQ4 2021
METAMeta Platforms, Inc.$18.8M4.76%Not reportedNot reportedQ1 2022
KLARKlarna Group plc$17.3M4.38%0.23%-68.6%Q3 2025
BABAAlibaba Group Holding Ltd$14.4M3.65%0.01%Not reportedQ4 2021
COFCapital One Financial Corp$9.63M2.44%0.01%NewQ2 2026
NMRANeumora Therapeutics, Inc.$7.58M1.92%2.41%Not reportedQ3 2023
MNDYmonday.com Ltd.$4.78M1.21%0.13%Not reportedQ4 2021
RKLBRocket Lab Corp$3.62M0.92%0.01%Not reportedQ1 2026
ACHRArcher Aviation Inc.$3.31M0.84%0.09%Not reportedQ2 2022
LYELLyell Immunopharma, Inc.$1.22M0.31%0.37%Not reportedQ4 2021
BLLNBillionToOne, Inc.$587K0.15%0.04%NewQ2 2026
Q1 2026Reported May 13, 202614 positions
HAYWHayward Holdings, Inc.$87.9M24.95%3.02%-21.0%Q3 2024
RVMDRevolution Medicines, Inc.$77.4M21.95%0.40%+56.5%Q4 2023
KLARKlarna Group plc$35.5M10.08%0.72%Not reportedQ3 2025
RXRXRecursion Pharmaceuticals, Inc.$29.6M8.40%1.82%Not reportedQ4 2021
QSRRestaurant Brands International Inc.$28.5M8.10%0.11%Not reportedQ4 2021
CPNGCoupang, Inc.$26.7M7.57%Not reportedNot reportedQ4 2021
METAMeta Platforms, Inc.$19.1M5.41%Not reportedNot reportedQ1 2022
GRABGrab Holdings Ltd$18.3M5.19%Not reportedNot reportedQ4 2021
NMRANeumora Therapeutics, Inc.$8.7M2.47%2.45%Not reportedQ3 2023
INSGInseego Corp.$8.53M2.42%4.73%NewQ1 2026
MNDYmonday.com Ltd.$4.56M1.29%0.13%Not reportedQ4 2021
ACHRArcher Aviation Inc.$3.62M1.03%0.09%Not reportedQ2 2022
RKLBRocket Lab Corp$2.29M0.65%0.01%NewQ1 2026
LYELLyell Immunopharma, Inc.$1.75M0.50%0.37%Not reportedQ4 2021
Q4 2025Reported Feb 17, 202613 positions
HAYWHayward Holdings, Inc.$129M29.14%3.83%-15.8%Q3 2024
KLARKlarna Group plc$78.5M17.79%0.72%Not reportedQ3 2025
RVMDRevolution Medicines, Inc.$40.5M9.18%0.26%Not reportedQ4 2023
RXRXRecursion Pharmaceuticals, Inc.$39.4M8.94%1.83%Not reportedQ4 2021
CPNGCoupang, Inc.$33.3M7.55%Not reportedNot reportedQ4 2021
QSRRestaurant Brands International Inc.$26.4M5.97%0.11%Not reportedQ4 2021
GRABGrab Holdings Ltd$25M5.65%Not reportedNot reportedQ4 2021
BABAAlibaba Group Holding Ltd$22M4.98%0.00%Not reportedQ4 2021
METAMeta Platforms, Inc.$22M4.98%Not reportedNot reportedQ1 2022
MNDYmonday.com Ltd.$9.74M2.21%0.13%Not reportedQ4 2021
NMRANeumora Therapeutics, Inc.$7.98M1.81%2.56%Not reportedQ3 2023
ACHRArcher Aviation Inc.$5.26M1.19%0.09%Not reportedQ2 2022
LYELLyell Immunopharma, Inc.$2.68M0.61%0.41%Not reportedQ4 2021
Q3 2025Reported Nov 14, 202513 positions
HAYWHayward Holdings, Inc.$149M29.85%4.55%-6.3%Q3 2024
KLARKlarna Group plc$99.5M19.89%Not reportedNewQ3 2025
RXRXRecursion Pharmaceuticals, Inc.$47.1M9.41%1.96%Not reportedQ4 2021
CPNGCoupang, Inc.$45.5M9.09%Not reportedNot reportedQ4 2021
GRABGrab Holdings Ltd$30.1M6.02%Not reportedNot reportedQ4 2021
BABAAlibaba Group Holding Ltd$26.8M5.36%0.00%Not reportedQ4 2021
QSRRestaurant Brands International Inc.$24.8M4.95%0.12%Not reportedQ4 2021
METAMeta Platforms, Inc.$24.5M4.89%Not reportedNot reportedQ1 2022
RVMDRevolution Medicines, Inc.$23.8M4.75%0.27%Not reportedQ4 2023
MNDYmonday.com Ltd.$12.8M2.55%0.13%Not reportedQ4 2021
NMRANeumora Therapeutics, Inc.$8.12M1.62%2.75%Not reportedQ3 2023
ACHRArcher Aviation Inc.$6.71M1.34%0.11%Not reportedQ2 2022
LYELLyell Immunopharma, Inc.$1.41M0.28%0.45%Not reportedQ4 2021
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.